Solstice Neurosciences is focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products.
Business Model:
Revenue: $0
Employees: 51-200
Solstice Neurosciences was acquired by
US WorldMeds.
The acquisition happend on 2010-08-13.
Details of the transaction were not public
Address:
City: South San Francisco
State: California
Zip:
Country: United States
Solstice Neurosciences is a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products. Solstice&s;s first product named Myobloc® (rimabotulinumtoxinB) Injection in the U.S. and NeuroBloc® (Botulinum Toxin Type B) Injectable Solution in select overseas markets, represents the only botulinum toxin type B currently available to physicians and patients worldwide.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 11/2006 | Series B | 5 | $85M |
Highland Capital Partners Investor Growth Capital Limited Morgan Stanley Venture Partners Oxford Bioscience Partners Thomas, McNerney &a; Partners Highland Capital Partners Investor Growth Capital Limited Morgan Stanley Venture Partners Oxford Bioscience Partners Thomas, McNerney &a; Partners |
7/2005 | Venture Round | 4 | $8M |
Investor Growth Capital Limited Morgan Stanley Venture Partners Oxford Bioscience Partners Thomas, McNerney &a; Partners Investor Growth Capital Limited Morgan Stanley Venture Partners Oxford Bioscience Partners Thomas, McNerney &a; Partners |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|